Bringing the fundamentals into focus…
Back to AbbVie Inc.
How AbbVie Inc. stacks up
ABBV · against 7 other Healthcare companies of similar size
Valuation
48/ 100
Near the bottom of its peers.
Ranked #8 of 8 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score1 peers with a valuation score of 40–49, including ABBV · Click a bar to see the companies
Why valuation scores 48?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- Earnings yield is close to the peer norm. Earnings yield: 1.2% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 4.3% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 71% of peers. Free cash flow yield: 3.6% vs peer median 0.0%
Metric by metric
Position: dot = ABBV, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ABBV | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 8 reported | 1.2% | 3.5% | 14% | 30% | |
| EBITDA yieldHigher is better · 8 reported | 5.4% | 6.5% | 29% | 50% | |
| Free cash flow yieldHigher is better · 7 reported | 3.6% | 3.6% | 50% | 20% | |
| Book yieldHigher is better · 8 reported | -1.2% | 13.5% | 0% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ABBV| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 317.9B CHF (≈$365.6B) | 70 | 60 | |
| 2 | 302.7B USD | 68 | 63 | |
| 3 | 285.2B USD | 66 | 63 | |
| 4 | 363.0B USD | 65 | 47 | |
| 5 | 641.4B USD | 58 | 59 | |
| 6 | 356.9B USD | 54 | 37 | |
| 7 | 258.2B USD | 53 | 47 | |
| 8 | 505.4B USD | 48 | 53 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score